Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03997448 · ClinicalTrials.gov registry record · Phase 2
Abemaciclib and Pembrolizumab in Locally Advanced Unresectable or Metastatic Gastroesophageal Adenocarcinoma: Big Ten Cancer Research Consortium BTCRC-GI18-149
A Phase 2 study, sponsored by Nataliya Uboha.
- Terminated
- Registry status
- Phase 2
- Development phase
- 3
- Enrollment target
NCT03997448 is a Phase 2 study that was terminated before completion, run by Nataliya Uboha. The registered enrollment target is 3 participants.
The verdict
NCT03997448, a Phase 2 study, was terminated before completion, sponsored by Nataliya Uboha.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 3 participants
- Enrollment target
Study Summary
This study will test the combination of abemaciclib with pembrolizumab in patients with gastric, gastroesophageal junction, or esophageal adenocarcinoma that is metastatic or cannot be surgically removed, and who have progressed on, or were unable to tolerate, at least 2 earlier courses of treatment for their advanced disease.
Interventions
- DRUG Pembrolizumab
- DRUG Abemaciclib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2019-08-26 |
| Est. Completion | 2020-01-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03997448
The ClinicalTrials.gov registry entry for NCT03997448 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 3 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Nataliya Uboha, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Pembrolizumab is the first listed.
NCT03997448 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03997448 about?
NCT03997448 is a clinical study titled "Abemaciclib and Pembrolizumab in Locally Advanced Unresectable or Metastatic Gastroesophageal Adenocarcinoma: Big Ten Cancer Research Consortium BTCRC-GI18-149". This study will test the combination of abemaciclib with pembrolizumab in patients with gastric, gastroesophageal junction, or esophageal adenocarcinoma that is metastatic or cannot be surgically removed, and who have progressed on, or were unable to tolerate, at least 2 earlier courses of treatment...
What is the current status of trial NCT03997448?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 3 participants. The study started on 2019-08-26. Estimated completion is 2020-01-30.
What interventions are being tested in trial NCT03997448?
The interventions under investigation include: Pembrolizumab (DRUG), Abemaciclib (DRUG).
Who is sponsoring clinical trial NCT03997448?
This trial is sponsored by Nataliya Uboha, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.